Julien Taı̈eb
1,137 works · 38,877 citations · h-index 88
Top works
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
- Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
- A novel dendritic cell subset involved in tumor immunosurveillance
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
- Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effects
- Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection
- Truth Survival in Clinical Research: An Evidence-Based Requiem?
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- Control of the Immune Response by Pro-Angiogenic Factors
- Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα
- Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
- SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer